S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
The Real Problem With "Made in America" Lithium (Ad)
What is a Growth Stock Mutual Fund?
Sprinklr Gets Targets Raised By Analysts, Here's Why
The Real Problem With "Made in America" Lithium (Ad)
10 Best Airline Stocks to Buy
Ollie’s Bargain Outlet Goes On Sale 
New "Mined in America" Lithium Opportunities? (Ad)
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
The Real Problem With "Made in America" Lithium (Ad)
What is a Growth Stock Mutual Fund?
Sprinklr Gets Targets Raised By Analysts, Here's Why
The Real Problem With "Made in America" Lithium (Ad)
10 Best Airline Stocks to Buy
Ollie’s Bargain Outlet Goes On Sale 
New "Mined in America" Lithium Opportunities? (Ad)
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
The Real Problem With "Made in America" Lithium (Ad)
What is a Growth Stock Mutual Fund?
Sprinklr Gets Targets Raised By Analysts, Here's Why
The Real Problem With "Made in America" Lithium (Ad)
10 Best Airline Stocks to Buy
Ollie’s Bargain Outlet Goes On Sale 
New "Mined in America" Lithium Opportunities? (Ad)
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
The Real Problem With "Made in America" Lithium (Ad)
What is a Growth Stock Mutual Fund?
Sprinklr Gets Targets Raised By Analysts, Here's Why
The Real Problem With "Made in America" Lithium (Ad)
10 Best Airline Stocks to Buy
Ollie’s Bargain Outlet Goes On Sale 
New "Mined in America" Lithium Opportunities? (Ad)
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Apple Partnership Strengthens Unity Software's Investment Appeal
Top-Rated StocksTop-Rated
NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Forecast, Price & News

$35.47
+0.67 (+1.93%)
(As of 06/7/2023 ET)
Compare
Today's Range
$34.94
▼
$36.19
50-Day Range
$28.53
▼
$39.55
52-Week Range
$11.07
▼
$47.25
Volume
877,697 shs
Average Volume
632,357 shs
Market Capitalization
$1.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.40
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Ventyx Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
56.2% Upside
$55.40 Price Target
Short Interest
Bearish
19.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.43mentions of Ventyx Biosciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$18.32 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.76) to ($3.39) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

597th out of 981 stocks

Pharmaceutical Preparations Industry

278th out of 460 stocks

See Top Rated MarketRank™ Stocks Here

VTYX stock logo

About Ventyx Biosciences (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company is developing VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

VTYX Stock News Headlines

June 7, 2023 | finance.yahoo.com
Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis
June 4, 2023 | americanbankingnews.com
William J. Sandborn Sells 10,629 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock
June 8, 2023 | Edge On The Street (Ad)
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
May 25, 2023 | americanbankingnews.com
Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $55.40
May 18, 2023 | americanbankingnews.com
William J. Sandborn Sells 3,487 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock
May 12, 2023 | markets.businessinsider.com
Ventyx Biosciences (VTYX) Gets a Buy from LifeSci Capital
May 12, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for Ventyx Biosciences
May 12, 2023 | msn.com
Preview: Ventyx Biosciences's Earnings
June 8, 2023 | Edge On The Street (Ad)
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
May 12, 2023 | finance.yahoo.com
Q1 2023 Ventyx Biosciences Inc Earnings Call
May 12, 2023 | finanznachrichten.de
Ventyx Biosciences, Inc.: Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
May 12, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)
May 12, 2023 | markets.businessinsider.com
Ventyx Biosciences (VTYX) Receives a Buy from Goldman Sachs
May 11, 2023 | msn.com
Recap: Ventyx Biosciences Q1 Earnings
May 11, 2023 | finance.yahoo.com
Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
May 9, 2023 | americanbankingnews.com
Ventyx Biosciences (VTYX) Scheduled to Post Quarterly Earnings on Thursday
May 8, 2023 | americanbankingnews.com
Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan Sells 30,000 Shares
May 4, 2023 | finance.yahoo.com
Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023
May 4, 2023 | americanbankingnews.com
Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider Sells 10,790 Shares of Stock
May 2, 2023 | americanbankingnews.com
Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Target Price at $55.40
May 2, 2023 | americanbankingnews.com
Financial Analysis: Ventyx Biosciences (VTYX) versus Its Peers
April 30, 2023 | americanbankingnews.com
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Sees Significant Decline in Short Interest
April 28, 2023 | americanbankingnews.com
Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Major Shareholder Sells 8,642 Shares of Stock
April 28, 2023 | americanbankingnews.com
Ventyx Biosciences, Inc. (NASDAQ:VTYX) CFO Martin Auster Sells 28,000 Shares
April 28, 2023 | americanbankingnews.com
Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Major Shareholder Sells $3,499,431.60 in Stock
April 27, 2023 | americanbankingnews.com
Somu Subramaniam Sells 793 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock
April 22, 2023 | americanbankingnews.com
Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) CFO Sells $231,000.00 in Stock
See More Headlines

VTYX Price History

VTYX Company Calendar

Last Earnings
3/23/2023
Today
6/08/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTYX
CUSIP
N/A
CIK
1851194
Web
www.ventyxbio.com
Phone
760-593-4832
Fax
N/A
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.40
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+56.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-108,430,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-36.87%
Return on Assets
-34.54%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
23.44
Quick Ratio
23.44

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.25 per share
Price / Book
5.68

Miscellaneous

Outstanding Shares
58,350,000
Free Float
44,118,000
Market Cap
$2.07 billion
Optionable
Not Optionable
Beta
-0.36

Key Executives

  • Dr. Sheila K. Gujrathi M.D. (Age 53)
    Exec. Chair
    Comp: $81.14k
  • Dr. Raju S. Mohan Ph.D. (Age 65)
    Founder, CEO & Director
    Comp: $783.73k
  • Dr. John M. Nuss Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $5.57M
  • Mr. Christopher W. Krueger J.D. (Age 55)
    MBA, Chief Bus. Officer
    Comp: $568.14k
  • Prof. William J. Sandborn M.D.
    Ph.D., Pres & Chief Medical Officer
  • Dr. Martin Douglas Auster M.D. (Age 48)
    Chief Financial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VTYX Stock - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTYX shares.
View VTYX analyst ratings or view top-rated stocks.

What is Ventyx Biosciences' stock price forecast for 2023?

8 equities research analysts have issued 1 year price targets for Ventyx Biosciences' stock. Their VTYX share price forecasts range from $35.00 to $77.00. On average, they anticipate the company's share price to reach $55.40 in the next year. This suggests a possible upside of 56.2% from the stock's current price.
View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2023?

Ventyx Biosciences' stock was trading at $32.79 on January 1st, 2023. Since then, VTYX shares have increased by 8.2% and is now trading at $35.47.
View the best growth stocks for 2023 here.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VTYX earnings forecast.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.03.

What ETFs hold Ventyx Biosciences' stock?

ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Alger Mid Cap 40 ETF (FRTY), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Nuveen Small Cap Select ETF (NSCS).

When did Ventyx Biosciences IPO?

(VTYX) raised $152 million in an initial public offering on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share.

What is Ventyx Biosciences' stock symbol?

Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX."

Who are Ventyx Biosciences' major shareholders?

Ventyx Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (13.35%), Price T Rowe Associates Inc. MD (4.71%), BlackRock Inc. (3.60%), RTW Investments LP (2.44%), Wellington Management Group LLP (1.53%) and Pictet Asset Management SA (1.31%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White.
View institutional ownership trends.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ventyx Biosciences' stock price today?

One share of VTYX stock can currently be purchased for approximately $35.47.

How much money does Ventyx Biosciences make?

Ventyx Biosciences (NASDAQ:VTYX) has a market capitalization of $2.07 billion. The company earns $-108,430,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

How can I contact Ventyx Biosciences?

The official website for the company is www.ventyxbio.com. The company can be reached via phone at 760-593-4832 or via email at ir@ventyxbio.com.

This page (NASDAQ:VTYX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -